Schott Pharma shares rose following an upgrade from Barclays, which cited expectations of a growth inflection for the company.
Barclays upgraded Schott Pharma, pointing to an anticipated growth inflection that drove the company's shares higher in market trading.
Specific financial terms and valuation details regarding the Barclays rating adjustment were not immediately disclosed.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →